BioTuesdays
Verastem
Markets

BTIG ups Verastem to buy from neutral; PT $8

BTIG upgraded Verastem (NASDAQ:VSTM) to “buy” from “neutral” with a new price target of $8, citing a breakthrough designation from the FDA for its KRAS-focused combination therapy of VS-6766 with defactinib for all...

May 24, 2021
Clene-Nanomedicine
Markets

Maxim starts Clene at buy; PT $18

Maxim Group launched coverage of Clene (NASDAQ:CLNN) with a “buy” rating and $18 price target. The stock closed at $8.95 on May 19. Clene is a clinical-stage company developing CNM-Au8, an oral, clean-surfaced faceted...

May 20, 2021
Neuropace
Markets

SVB Leerink starts NeuroPace at OP; PT $25

SVB Leerink initiated coverage of Neuropace (NASDAQ:NPCE) with an “outperform” rating and $25 price target. The stock closed at $20.91 on May 14. “To us, NeuroPace represents a top-tier growth profile SMID-cap MedTech...

May 17, 2021
Dyadic
Markets

Dawson James halves Dyadic PT to $6 from $12

Dawson James reduced its price target for Dyadic (NASDAQ:DYAI) to $6 from $12, citing uncertainty about the potential of its COVID-19 vaccine. The stock closed at $3.73 on May 14. “DYAI-100 (COVID) is advancing to human...

May 17, 2021
Annovis Logo
Markets

Maxim ups Annovis Bio PT to $45 from $12

Maxim Group raised its price target for Annovis Bio (NYSE American: ANVS) to $45 from $12, citing upcoming Phase 2a data evaluating ANVS401 in Alzheimer’s disease (AD) and Parkinson’s disease (PD) patients. The stock...

May 13, 2021
4D-Pharma-PLC
Markets

Ladenburg starts 4D Pharma at buy; PT $35

Ladenburg Thalmann launched coverage of 4D Pharma PLC (NASDAQ:LBPS) with a “buy” rating and $35 price target. The stock closed at $10.55 on May 12. 4D Pharma is a Leeds, UK-based biotechnology company developing live...

May 13, 2021
Catabasis Pharma
Markets

Ladenburg starts Catabasis Pharma at buy; PT $6

Ladenburg Thalmann launched coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and price target of $8. The stock closed at $1.78 on May 11. Catabasis is a Boston-based biotechnology company focused...

May 12, 2021
Intercept-Pharma
Markets

Cantor cuts Intercept Pharma PT to $23 from $45

Cantor Fitzgerald reduced its price target for Intercept Pharmaceuticals (NASDAQ:ICPT) to $23 from $45 and maintained its “neutral” rating, citing first quarter financial results “which we think highlighted a lot of the...

May 7, 2021
CTIBiopharmaLogo
Markets

Stifel starts CTI Biopharma at buy; PT $5.50

Stifel initiated coverage of CTI Biopharma (NASDAQ:CTIC) with a “buy” rating and price target of $5.50. The stock closed at $2.34 on May 5. “We think the bull/bear debate on CTI Biopharma centers around the size of the...

May 6, 2021
iTeos Logo
Markets

HCW starts iTeos Therapeutics at buy; PT $37

H.C. Wainwright launched coverage of iTeos Therapeutics (NASDAQ:ITOS) with a “buy” rating and $37 price target. The stock finished at $23.03 on May 4. ITeos Therapeutics, which is developing next-generation immuno...

May 5, 2021
Mereo-BioPharma
Markets

BTIG starts Mereo Biopharma at buy; PT $10

BTIG initiated coverage of Mereo Biopharma (NASDAQ:MREO) with a “buy” rating and price target of $10. The stock closed at $3.49 on May 4. “We believe Mereo shares are significantly undervalued with abundant proof-of...

May 5, 2021
Markets

Maxim doubles BioLineRx PT to $10 from $5

Maxim Group raised its price target for BioLineRx (NASDAQ:BLRX) to $10 from $5 on positive top-line data from the company’s Phase 3 GENESIS trial. The stock was quoted at $5.30, up $2.11, in afternoon trading on...

May 4, 2021
Vectiv-Bio
Markets

SVB Leerink starts VectivBio at OP; PT $28

SVB Leerink launched coverage of VectivBio Holding AG (NASDAQ:VECT) with an “outperform” rating and $28 price target. The stock closed at $15.21 on May 3. VectivBio is focused on developing treatments for severe rare...

May 4, 2021
Lucira-Health-Logo
Markets

WB cuts Lucira Heath to market perform

William Blair downgraded Lucira Health (NASDAQ:LHDX) to “market perform,” citing changes to the testing market that have played out over the last couple of months coupled with lack of demand for the company’s at-home...

May 4, 2021
ProQR
Markets

Stifel starts ProQR Therapeutics at buy; PT $20

Stifel initiated coverage of ProQR Therapeutics N.V. (NASDAQ:PRQP) with a “buy” rating and price target of $20. The stock finished at $6.22 on April 30. “As a clinical-stage company with demonstrated proof-of-concept...

May 3, 2021
AVROBIO
Markets

SVB Leerink cuts AVROBIO PT to $10 from $18

SVB Leerink reduced its price target for AVROBIO (NASDAQ:AVRO) to $10 from $18 but maintained its “market perform” rating after the company announced that it may no longer pursue an accelerated approval pathway for AVR...

May 3, 2021
Clene-Nanomedicine
Markets

Cantor starts Clene at OW; PT $22

Cantor Fitzgerald launched coverage of Clene (NASDAQ:CLNN) with an “overweight” rating and 12-month price target of $22. The stock closed at $9 on April 30. Clene is a neuro-innovator that is developing drugs to enhance...

May 3, 2021
DermTech-Logo
Markets

BTIG starts DermTech at buy; PT $53

BTIG initiated coverage of DermTech (NASDAQ:DMTK) with a “buy” rating and $53 price target. The stock closed at $42.05 on April 30. DermTech provides genomic diagnostic testing for various skin diseases and conditions...

May 3, 2021
SioGene-Therapies
Markets

HCW starts Sio Gene Therapies at buy; PT $8

H.C. Wainwright initiated coverage of Sio Gene Therapies (NASDAQ:SIOX) with a “buy” rating and price target of $8. The stock closed at $2.70 on April 29. Sio is a gene therapy company with significant experience and...

April 30, 2021
Cardiol Therapeutics
Markets

Raymond James ups Cardiol Therapeutics to OP from MP

Raymond James upgraded Cardiol Therapeutics (TSX:CRDL) to “outperform” from “market perform,” citing enrollment of the first patient in a Phase 2/3 clinical trial investigating the cardioprotective properties of...

April 28, 2021